ArticleInternational journal of general medicine2026
Serum Untargeted Metabolomics Profiling of Esophageal Squamous Cell Carcinoma in High-Incidence Areas of China.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a frequent malignant tumor arising in the upper gastrointestinal tract, esophageal squamous cell carcinoma (ESCC) exhibits an exceptionally high prevalence in China. Metabolic reprogramming is a hallmark of cancer, and serum metabolites have been implicated in the development of various gastrointestinal cancers. However, their role in ESCC remains to be further elucidated. Objective: The present research sought to characterize the differences in serum metabolism between patients with ESCC and healthy controls (HCs), and explore their potential roles in ESCC initiation. Methods: From September 2023 to September 2024, 70 previously untreated ESCC patients and 72 matched HCs were recruited. Serum untargeted metabolomics was analyzed by ultra‑high performance liquid chromatography‑Orbitrap‑tandem mass spectrometry (UHPLC‑Orbitrap‑MS/MS), followed by bioinformatic analysis. Results: Compared with HCs, 713 differentially expressed metabolites were identified in ESCC patients, with lipids and lipid‑like molecules representing the biggest category (16.1%). Enrichment analysis of metabolic pathways indicated that biosynthesis of unsaturated fatty acids (UFAs) was the most significantly dysregulated pathway ( Conclusion: This study demonstrates significant serum metabolic alterations in ESCC patients, particularly in lipid metabolism and UFA biosynthesis. The seven‑metabolite panel shows favorable discriminatory performance for ESCC, suggesting their potential as biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.